Vnitr Lek 2025, 71(4):261-264 | DOI: 10.36290/vnl.2025.047

Advances in the treatment of heat failure

Filip Málek
Kardiologická klinika 1. LF UK a Nemocnice Na Homolce, Praha

Advances in pharmacotherapy have brought new possibilities in the treatment of heart failure. Therapy of heart failure with reduced ejection fraction has four basic pillars - fundamental drugs. Update of heart failure guidelines extended new options in the treatment of heart failure with preserved and mildly reduced ejection fraction. In additon to sodium glucose co-transporter 2 inhibitors, it is a hope for patients with heart failure and ejection fraction over 40 % selective non-steroideal mineralocorticoid receptro antagonist - finerenon.

Keywords: pharmcotherapy, heart failure disease modifying drugs, gliflozins, finerenon.

Accepted: June 3, 2025; Published: June 19, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Advances in the treatment of heat failure. Vnitr Lek. 2025;71(4):261-264. doi: 10.36290/vnl.2025.047.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726. Go to original source... Go to PubMed...
    2. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J. 2023;OO:1-13. Go to original source...
    3. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    4. Circulation. 2022;145:e895-e1032.
    5. Málek F, Veselý J, Pudil R, et al. Doporučení ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání 2021: Pracovní skupina pro diagnostiku a léčbu akutního a chronického srdečního selhání Evropské kardiologické společnosti (ESC) se zvláštním přispěním Evropské asociace srdečního selhání ESC. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. Překlad zkráceného dokumentu připravený Českou kardiologickou společností. Cor Vasa. 2022;64(Suppl. 3):4-55. Go to original source...
    6. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938-1952. Go to original source... Go to PubMed...
    7. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction N Engl J Med. 2021, doi: 10.1056/NEJMoa210703. Go to original source...
    8. Solomon SD, McMurray JJV, Claggett B, et al. For the DELIVER Trial Committees and Investigators Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction N Engl J Med. 2022;387:1089-1098. Go to original source... Go to PubMed...
    9. Maurer MS, Schwartz JH, Gundapaneni Bet al. ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.N Engl J Med. 2018 Sep 13;379(11):1007-1016. Go to original source... Go to PubMed...
    10. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759-69. 10. 1016/S0140-6736(20)31792-X. Go to original source... Go to PubMed...
    11. Solomon SD, McMurray JJ, Vaduganathan M, et al., for the FINEARTS-HF Committees and Investigators. Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391:1475-85. Go to original source... Go to PubMed...
    12. Bakris GL, Agarwal R, Anker SD, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219-2229. Go to original source... Go to PubMed...
    13. Pitt B, Filippatos G, Agarwal R, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252-2263. Go to original source... Go to PubMed...
    14. Dvořák R, Souček M. Finerenon: další možnost léčby u pacientů s chronickým onemocněním ledvin a diabetem 2. typu. Vnitř Lék. 2023;69(5):335-338.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.